Repository logo
 
Publication

DNA and BSA binding and cytotoxic properties of copper(II) and iron(III) complexes with arylhydrazone of ethyl 2-cyanoacetate or formazan ligands

dc.contributor.authorMartins, Nuno
dc.contributor.authorSellamuthu, Anbu
dc.contributor.authorMahmudov, Kamran
dc.contributor.authorRavishankaran, Rajendran
dc.contributor.authorGuedes Da Silva, M. Fátima C.
dc.contributor.authorMartins, Luisa
dc.contributor.authorKarande, Anjali A.
dc.contributor.authorPombeiro, Armando
dc.date.accessioned2017-04-27T07:45:38Z
dc.date.available2017-04-27T07:45:38Z
dc.date.issued2017-05-21
dc.description.abstractSeveral known water soluble [Cu(1N,O2:2O-HL1)(S)]2 [S = CH3OH (1), (CH3)2NCHO (2)] and [Cu(N-HL1)(en)2]∙CH3OH∙H2O (3) CuII complexes were prepared by reaction of CuII nitrate hydrate with the new (E/Z)-4-(2-(1-cyano-2-ethoxy-2-oxoethylidene)hydrazinyl)-3-hydroxybenzoic acid (H3L1), in the presence (for 3) or absence (for 1 and 2) of ethylenediamine (en), while the FeIII complex [Fe(N3-HL2)2] (4) was synthesized by treatment of iron(III) chloride hexahydrate with the new (1E,1E)-N',2-di(1H-1,2,4-triazol-3-yl)diazenecarbohydrazonoyl cyanide (H3L2). The interaction of calf thymus DNA (CT DNA) and bovine serum albumin (BSA protein) with complexes 1−4 has been investigated by absorption and fluorescence titration methods. The observed DNA binding constants, number of DNA binding sites (s ≤ 1) for complexes and viscosity data suggest that the intercalative mode of binding to CT DNA. All the complexes show good binding propensity to the BSA, giving KBSA values of 0.97(±0.10) × 106 (1), 1.19(±0.09) × 106 (2), 0.50(±0.01) × 106 (3) and 1.06(±0.08) × 106 M-1 (4). The in vitro anti-proliferative study establishes the anticancer potency of complexes 1−4 and cisplatin against the human cervical (HeLa) and breast (MCF7) cancer cell lines; noncancer breast epithelial (MCF10) cells were also investigated. The observed IC50 values of the complexes 1 (8.3, 11.9 and 44.8 μM), 2 (7.0, 7.1 and 35.6 μM), 3 (18.1, 20.4 and 58.8 μM), 4 (13.2, 15.1 and 79.4 μM) and cisplatin (4.02, 3.42 and 89.5 μM) against the HeLa, MCF7 and MCF-10a cells, respectively, suggest that 2 can be explored further as a potential anticancer drug.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationMARTINS, Nuno M. R.; [et al] – DNA and BSA binding and cytotoxic properties of copper(II) and iron(III) complexes with arylhydrazone of ethyl 2-cyanoacetate or formazan ligands. New Journal of Chemistry. ISSN 1144-0546. Vol. 41, N.º 10 (2017), pp.1-20pt_PT
dc.identifier.doi10.1039/C7NJ00420Fpt_PT
dc.identifier.issn1144-0546
dc.identifier.issn1369-9261
dc.identifier.urihttp://hdl.handle.net/10400.21/6953
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherRoyal Society of Chemistrypt_PT
dc.relation.publisherversionhttp://pubs.rsc.org/en/content/articlepdf/2017/NJ/C7NJ00420Fpt_PT
dc.titleDNA and BSA binding and cytotoxic properties of copper(II) and iron(III) complexes with arylhydrazone of ethyl 2-cyanoacetate or formazan ligandspt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage20pt_PT
oaire.citation.issue10
oaire.citation.startPage1pt_PT
oaire.citation.titleNew Journal of Chemistrypt_PT
oaire.citation.volume41
person.familyNameMartins
person.familyNameMahmudov
person.familyNameGuedes da Silva
person.familyNameMartins
person.familyNamePombeiro
person.givenNameNuno
person.givenNameKamran
person.givenNameM. Fátima C.
person.givenNameLuisa
person.givenNameArmando
person.identifier789079
person.identifier637885
person.identifier.ciencia-idCD1F-CB64-9EA5
person.identifier.ciencia-id7619-8E8E-979A
person.identifier.ciencia-idE218-E297-A4EA
person.identifier.ciencia-id8311-38FA-CEFB
person.identifier.orcid0000-0001-7787-6041
person.identifier.orcid0000-0003-0743-6520
person.identifier.orcid0000-0003-4836-2409
person.identifier.orcid0000-0002-5403-9352
person.identifier.orcid0000-0001-8323-888X
person.identifier.ridG-3485-2017
person.identifier.ridI-1409-2013
person.identifier.ridH-8274-2012
person.identifier.ridG-6210-2011
person.identifier.ridI-5945-2012
person.identifier.scopus-author-id57189394320
person.identifier.scopus-author-id24468352000
person.identifier.scopus-author-id6701761571
person.identifier.scopus-author-id8650947800
person.identifier.scopus-author-id7006067269
rcaap.rightsclosedAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublicationb8a284fb-6a64-47e8-9633-fe3a789b5707
relation.isAuthorOfPublication71d8ce81-a614-49c5-8606-e351da465649
relation.isAuthorOfPublication18e14ad3-9937-46d0-83b2-36fab224c1c0
relation.isAuthorOfPublication8ed70b09-b4d3-4a5d-9f75-12b13a332204
relation.isAuthorOfPublication6d18ff2e-5c33-4010-b1e7-964c72349813
relation.isAuthorOfPublication.latestForDiscovery8ed70b09-b4d3-4a5d-9f75-12b13a332204

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
DNA_LMMartins_ADEQ.pdf
Size:
2.09 MB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: